Cargando…
Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
This article illustrates a consensus opinion of an expert panel on the need and usefulness of a framework for price and reimbursement (P&R) process and managed entry agreements (MEAs) for orphan medicines in Italy. This opinion was gathered in three rounds: an introductory document was sent to t...
Autores principales: | Jommi, Claudio, Addis, Antonio, Martini, Nello, Nicod, Elena, Pani, Marcello, Scopinaro, Annalisa, Vogler, Sabine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AboutScience
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616180/ https://www.ncbi.nlm.nih.gov/pubmed/36627869 http://dx.doi.org/10.33393/grhta.2021.2278 |
Ejemplares similares
-
Prezzo e rimborso dei farmaci in caso di estensione delle indicazioni: i risultati di una survey sui soci di ISPOR Italy Rome Chapter
por: Di Brino, Eugenio, et al.
Publicado: (2023) -
Orphan CpG islands as alternative promoters
por: Sarda, Shrutii, et al.
Publicado: (2017) -
How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
por: Russo, Pierluigi
Publicado: (2022) -
Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011) -
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency
por: Zangrillo, Alberto, et al.
Publicado: (2023)